Roles of PTPN11 in regulating and driving epithelial cancer
Roles of PTPN11 in regulating and driving epithelial cancer
批准号:
8698356
负责人:
JIE WU
金额:
$33.91万
依托单位国家:
美国
项目类别:
财政年份:
2013
资助国家:
美国
项目状态:
已结题
起止时间:
2013-07-08 至 2018-04-30
关键词:
AddressAffectAmericanAmericasAnimalsAutomobile DrivingC-terminalCancer EtiologyCancer PatientCarcinogensCarcinomaCessation of lifeCommunitiesDataDependencyDevelopmentDiseaseEnzymesEpidermal Growth Factor ReceptorEpithelialEpithelial CellsEventGRB2 geneGoalsHumanHuman ActivitiesInterventionKRAS2 geneKnowledgeLifeLungLung AdenocarcinomaLung NeoplasmsMalignant - descriptorMalignant NeoplasmsMalignant neoplasm of lungMalignant neoplasm of prostateMeasuresMediatingMedicalMutationOncogenesOncogenicPTPN11 genePathway interactionsPhosphorylationPhosphotyrosinePlayPreventivePreventive InterventionPropertyProtein Tyrosine KinaseProtein Tyrosine PhosphataseProteomicsRecruitment ActivityResearchResourcesRoleSignal TransductionSmokerSolid NeoplasmTestingTherapeutic InterventionTransgenic MiceTumor Suppressor ProteinsTyrosine Phosphorylationcigarette smokinghuman diseaseimprovedin vivoinsightlung Carcinomalung xenograftmouse modelmutantnever smokernon-smokernovelpreventpublic health relevancerecombinaseresearch studytooltumortumor growthtumorigenic
中文摘要
描述(由申请人提供):肺癌是一种未满足医疗需求的重大疾病。鉴定在调节肺恶性通路中起关键作用的分子
英文摘要
DESCRIPTION (provided by applicant): Lung cancer is a major disease with unmet medical need. Identification of molecules that play critical roles in regulating lung malignant pathways is
essential for improving the preventive and therapeutic interventions of this fatal disease. The goal of this study is to investigate the roles of PTPN11 (SHP2) in epithelial tumors focusing on lung adenocarcinoma. Mutant EGFR is a major lung adenocarcinoma driver oncogene found in never-smokers. Using novel transgenic mice, we will investigate in Specific Aim 1 whether SHP2 is essential for EGFR mutant-driven lung tumor and study mechanisms by which SHP2 mediates EGFR signaling and lung tumor development. Mutant KRAS is a major lung adenocarcinoma driver oncogene associated with heavy smokers. In Specific Aim 2, we will evaluate the SHP2 dependency of KRAS mutant lung adenocarcinoma and whether SHP2 inhibition prevents cigarette smoke carcinogen-induced lung tumors in transgenic mice. Animal lung and xenograft tumors will be analyzed by quantitative phosphoproteomics to gain insights into the mechanisms of SHP2 dependency of mutant EGFR and KRAS lung carcinoma in vivo. Previous studies of driver oncogenes have been focused on protein tyrosine kinases, while protein tyrosine phosphatases were perceived mostly as tumor suppressors. Consequently, there is near complete lack of knowledge about protein tyrosine phosphatase driver oncogenes in lung adenocarcinoma. PTPN11 mutations occur in lung adenocarcinoma and prostate cancer among other solid tumors. However, it is unclear whether these are passenger mutations or driver oncogene mutations in carcinoma and what properties confer a PTPN11 mutation the oncogenic activity in epithelial cells. In Specific Aim 3, we will analyze oncogenic activities of several PTPN11 mutations in lung epithelial cells to gain insights into the oncogenic activity of PTPN11 mutations in lung cancer. Taken together, this study could reveal important roles of a protein tyrosine phosphatase in two major lung cancer driver oncogene-associated lung adenocarcinoma. It will give novel insights into signaling events critical to both non-smoker and smoker-associated lung adenocarcinoma. In addition to the potential translational significance, by demonstrating the first protein tyrosine phosphatase driver oncogene in epithelial tumors and revealing the SHP2 dependency of KRAS mutant lung adenocarcinoma, the study could have significant conceptual impact in the field. Moreover, the novel Cre recombinase-mediated cassette exchange-enable transgenic mice characterized in this study will give the research community an important resource to accelerate mouse model studies of human diseases.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Modeling the KIF5B-RET Fusion Gene of Lung Cancer in Vivo
-
批准号:8617823
-
项目类别:
-
资助金额:$21.33万
-
财政年份:2013
-
负责人:JIE WU
-
依托单位:
Modeling the KIF5B-RET Fusion Gene of Lung Cancer in Vivo
-
批准号:8490695
-
项目类别:
-
资助金额:$18.32万
-
财政年份:2013
-
负责人:JIE WU
-
依托单位:
Roles of PTPN11 in regulating and driving epithelial cancer
-
批准号:8562206
-
项目类别:
-
资助金额:$34.96万
-
财政年份:2013
-
负责人:JIE WU
-
依托单位:
GABAergic excitation in human hypothalamic hamartoma
-
批准号:7135841
-
项目类别:
-
资助金额:$20.17万
-
财政年份:2006
-
负责人:JIE WU
-
依托单位:
GABAergic excitation in human hypothalamic hamartoma
-
批准号:7244003
-
项目类别:
-
资助金额:$17.59万
-
财政年份:2006
-
负责人:JIE WU
-
依托单位:
Development of SHP2-selective Phosphatase Inhibitors for Cancer Therapy
-
批准号:7214569
-
项目类别:
-
资助金额:$26.19万
-
财政年份:2006
-
负责人:JIE WU
-
依托单位:
Modulation of ErbB Signaling
-
批准号:6613165
-
项目类别:
-
资助金额:$29.01万
-
财政年份:1999
-
负责人:JIE WU
-
依托单位:
SIGNAL TRANSDUCTION BY LYSOPHOSPHATIDIC ACID
-
批准号:6137658
-
项目类别:
-
资助金额:$9.86万
-
财政年份:1999
-
负责人:JIE WU
-
依托单位:
SIGNAL TRANSDUCTION BY LYSOPHOSPHATIDIC ACID
-
批准号:6626600
-
项目类别:
-
资助金额:$10.77万
-
财政年份:1999
-
负责人:JIE WU
-
依托单位:
SIGNAL TRANSDUCTION BY LYSOPHOSPHATIDIC ACID
-
批准号:6489133
-
项目类别:
-
资助金额:$10.46万
-
财政年份:1999
-
负责人:JIE WU
-
依托单位:
Modulation of ErbB Signaling
-
批准号:6914376
-
项目类别:
-
资助金额:$29.01万
-
财政年份:1999
-
负责人:JIE WU
-
依托单位:
Modulation of ErbB Signaling
-
批准号:6785826
-
项目类别:
-
资助金额:$29.01万
-
财政年份:1999
-
负责人:JIE WU
-
依托单位:
SIGNAL TRANSDUCTION BY LYSOPHOSPHATIDIC ACID
-
批准号:6342079
-
项目类别:
-
资助金额:$10.16万
-
财政年份:1999
-
负责人:JIE WU
-
依托单位:
Modulation of ErbB Signaling
-
批准号:7091702
-
项目类别:
-
资助金额:$28.33万
-
财政年份:1999
-
负责人:JIE WU
-
依托单位:
Modulation of ErbB Signaling
-
批准号:7224922
-
项目类别:
-
资助金额:$27.51万
-
财政年份:1999
-
负责人:JIE WU
-
依托单位:
SIGNAL TRANSDUCTION BY LYSOPHOSPHATIDIC ACID
-
批准号:2751398
-
项目类别:
-
资助金额:$9.57万
-
财政年份:1999
-
负责人:JIE WU
-
依托单位:
Development of SHP2-selective Phosphatase Inhibitors for Cancer Therapy
-
批准号:7767739
-
项目类别:
-
资助金额:$29.08万
-
财政年份:--
-
负责人:JIE WU
-
依托单位:
Development of SHP2-selective Phosphatase Inhibitors for Cancer Therapy
-
批准号:8034264
-
项目类别:
-
资助金额:$29.71万
-
财政年份:--
-
负责人:JIE WU
-
依托单位:
Development of SHP2-selective Phosphatase Inhibitors for Cancer Therapy
-
批准号:8214732
-
项目类别:
-
资助金额:$27.55万
-
财政年份:--
-
负责人:JIE WU
-
依托单位:
海外基金